Top Page
Livzon Pharmaceutical Group
(1513)
Livzon Pharmaceutical Group (1513) vs. iShares MSCI Hong Kong ETF (EWH)
Livzon Pharmaceutical Group Business Overview & Revenue Model
Livzon Pharmaceutical Group Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 11.85B | 11.81B | 12.43B | 12.63B | 12.06B | 10.52B |
| Gross Profit | 7.81B | 7.73B | 7.66B | 8.17B | 7.81B | 6.85B |
| EBITDA | 3.05B | 3.47B | 3.33B | 3.08B | 2.77B | 2.91B |
| Net Income | 2.14B | 2.06B | 1.95B | 1.91B | 1.78B | 1.71B |
Balance Sheet | ||||||
| Total Assets | 24.54B | 24.46B | 25.04B | 24.86B | 22.37B | 20.59B |
| Cash, Cash Equivalents and Short-Term Investments | 11.04B | 10.92B | 11.41B | 10.52B | 9.33B | 9.98B |
| Total Debt | 4.66B | 3.93B | 3.48B | 3.62B | 2.69B | 1.93B |
| Total Liabilities | 9.17B | 9.55B | 10.28B | 9.93B | 8.06B | 6.95B |
| Stockholders Equity | 13.96B | 13.86B | 14.04B | 13.88B | 13.00B | 12.11B |
Cash Flow | ||||||
| Free Cash Flow | 2.57B | 2.41B | 2.43B | 1.83B | 593.23M | 1.51B |
| Operating Cash Flow | 2.56B | 2.98B | 3.25B | 2.77B | 1.90B | 2.16B |
| Investing Cash Flow | -1.65B | -660.33M | -708.37M | -1.23B | -1.88B | -467.84M |
| Financing Cash Flow | -2.37B | -2.49B | -1.66B | -720.36M | -815.02M | -518.04M |
Livzon Pharmaceutical Group Technical Analysis
Livzon Pharmaceutical Group Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | HK$27.76B | 13.17 | 12.65% | 3.13% | 10.56% | -13.58% | |
72 Outperform | HK$31.92B | 11.33 | 14.91% | 4.09% | -0.45% | 9.00% | |
68 Neutral | HK$28.59B | 9.40 | 5.90% | 2.95% | ― | ― | |
65 Neutral | HK$34.23B | 19.13 | 10.01% | 2.26% | 11.78% | 19.06% | |
64 Neutral | HK$23.48B | 6.55 | 21.02% | 5.11% | 0.39% | 4.94% | |
61 Neutral | HK$44.07B | 9.60 | 7.86% | 7.15% | 1.13% | -13.53% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
Livzon Pharmaceutical Group Corporate Events
Livzon Pharmaceutical Group’s subsidiary Livzon MABPharm has secured inclusion of its innovative biologic Lecankitug Injection in China’s priority review and approval process for marketing authorization, targeting adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. As the first domestically developed and second globally developed dual IL-17A/F inhibitor, Lecankitug demonstrated superior efficacy and a favorable safety profile versus secukinumab in a Phase III trial, underscoring the company’s strengthening position in high-value dermatology biologics and potentially accelerating time-to-market in a large, underserved psoriasis population, though regulatory and competitive uncertainties remain for investors and other stakeholders.
The most recent analyst rating on (HK:1513) stock is a Buy with a HK$32.00 price target. To see the full list of analyst forecasts on Livzon Pharmaceutical Group stock, see the HK:1513 Stock Forecast page.
Livzon Pharmaceutical Group has agreed to a connected transaction involving a capital increase and equity transfer at its subsidiary Fluffy Buddy, under which Xinyou Maohai will inject RMB15 million into Fluffy Buddy and acquire Joincare’s 49% stake, resulting in Xinyou Maohai holding 52.56% and Livzon’s stake being diluted from 51% to 47.44%. As a result, Fluffy Buddy will cease to be consolidated into Livzon’s financial statements, and the deal is classified under Hong Kong Listing Rules as a deemed disposal and connected transaction subject only to reporting and announcement requirements, indicating a restructuring of Livzon’s exposure to this business without triggering shareholder approval or major disclosure obligations.
The most recent analyst rating on (HK:1513) stock is a Sell with a HK$37.23 price target. To see the full list of analyst forecasts on Livzon Pharmaceutical Group stock, see the HK:1513 Stock Forecast page.
Livzon Pharmaceutical Group has amended the terms of its planned acquisition of a controlling stake in Vietnam’s Imexpharm Corporation, extending the deadline for completion to 30 June 2026 and clarifying merger control conditions to ensure regulatory compliance. With all conditions precedent now satisfied, the company’s board has approved an intended public tender offer to all Imexpharm shareholders, lifting the maximum potential consideration to approximately VND6.89 trillion (about RMB1.846 billion). As the deal now triggers a mandatory tender offer under Vietnamese securities rules, it will proceed as a discloseable transaction under Hong Kong Listing Rules without requiring independent shareholder approval, marking a significant step in Livzon’s push to deepen its presence in the Vietnamese pharmaceutical market, subject to final clearance by Vietnamese regulators.
The most recent analyst rating on (HK:1513) stock is a Sell with a HK$37.23 price target. To see the full list of analyst forecasts on Livzon Pharmaceutical Group stock, see the HK:1513 Stock Forecast page.
Livzon Pharmaceutical Group has approved and signed a series of 2026 framework agreements with its connected subsidiary Livzon MAB to govern continuing connected transactions for the year ending 31 December 2026. Under these agreements, the group will supply water, electricity, steam, natural gas and sewage treatment services, lease assets, purchase drugs from Livzon MAB, and provide labour services, with respective annual caps of RMB20 million, RMB35 million, RMB75 million and RMB80.5 million. As Livzon MAB is deemed a connected person through common shareholding by controlling shareholder Joincare, these arrangements fall under continuing connected transactions as defined by Hong Kong Listing Rules, triggering reporting and announcement obligations but remaining exempt from shareholder approval due to their size. The structured caps and formalized contracts underscore the company’s efforts to standardize intra-group dealings, support Livzon MAB’s operations and ensure regulatory compliance, while clarifying the financial scope of related-party transactions for investors and other stakeholders.
The most recent analyst rating on (HK:1513) stock is a Sell with a HK$37.23 price target. To see the full list of analyst forecasts on Livzon Pharmaceutical Group stock, see the HK:1513 Stock Forecast page.
Livzon Pharmaceutical Group has approved a new series of continuing connected transactions with its controlling shareholder Joincare for the 2026 financial year, covering the supply of utilities, mutual provision of labour services, and the sale and purchase of products between the two groups. The parties have signed five framework agreements effective from 1 January to 31 December 2026, with annual caps of RMB36 million for water, electricity, steam, natural gas and sewage treatment, RMB33 million and RMB170 million for the receipt and provision of labour services, and RMB38 million and RMB310 million for product sales and purchases respectively. As the percentage ratios for these transactions fall between 0.1% and 5% under Hong Kong Listing Rules, they are classified as continuing connected transactions requiring public reporting and announcement but are exempt from independent shareholders’ approval, underscoring Livzon’s ongoing operational reliance on related-party arrangements while remaining within regulatory thresholds for such dealings.
The most recent analyst rating on (HK:1513) stock is a Sell with a HK$37.23 price target. To see the full list of analyst forecasts on Livzon Pharmaceutical Group stock, see the HK:1513 Stock Forecast page.
Livzon MABPharm has had its marketing authorization application for Lecankitug Injection, a domestically developed Class 1 therapeutic biological product for adult patients with moderate-to-severe plaque psoriasis, formally accepted for review by China’s National Medical Products Administration. Lecankitug is the first domestically developed and second globally developed dual IL-17A/F inhibitor, and Phase III trial results showed superior efficacy and comparable safety versus secukinumab, positioning Livzon to potentially strengthen its competitiveness in China’s psoriasis treatment market and broaden its innovative biologics portfolio if approval is granted.
The most recent analyst rating on (HK:1513) stock is a Sell with a HK$37.23 price target. To see the full list of analyst forecasts on Livzon Pharmaceutical Group stock, see the HK:1513 Stock Forecast page.
Livzon Pharmaceutical Group announced that its subsidiary has received approval from China’s National Medical Products Administration to initiate clinical trials of NS-041 Tablet for an additional indication in the treatment of depression. NS-041 is a novel, highly selective KCNQ2/3 agonist and currently the only drug of its class in China cleared for clinical studies in both epilepsy and depression, with a Phase II epilepsy trial already under way. Preclinical data indicate favorable antidepressant effects and high target selectivity without observed ocular toxicity, and Livzon holds exclusive Greater China rights under a 2024 licensing deal with NeuShen Therapeutics. The move underscores Livzon’s push into innovative neuropsychiatric therapies and, given the lack of marketed next-generation KCNQ2/3-targeting drugs in China, could strengthen its competitive position if clinical results prove positive.
The most recent analyst rating on (HK:1513) stock is a Sell with a HK$37.23 price target. To see the full list of analyst forecasts on Livzon Pharmaceutical Group stock, see the HK:1513 Stock Forecast page.
Livzon Pharmaceutical Group Inc. announced the election of Ms. Wang Zhiyao as an Independent Non-Executive Director and Ms. Ran Yongmei as an Employee Representative Director to its eleventh session of the Board. These appointments strengthen the company’s governance structure, ensuring compliance with regulatory requirements and enhancing representation within the board. The inclusion of Ms. Wang and Ms. Ran is expected to bring diverse perspectives and expertise, potentially impacting the company’s strategic direction and stakeholder engagement positively.
The most recent analyst rating on (HK:1513) stock is a Sell with a HK$37.23 price target. To see the full list of analyst forecasts on Livzon Pharmaceutical Group stock, see the HK:1513 Stock Forecast page.
Livzon Pharmaceutical Group Inc. announced that all resolutions proposed at its 2025 First Extraordinary General Meeting were approved by shareholders. The meeting saw participation from a significant number of shareholders and proxies, representing over half of the company’s voting shares, indicating strong shareholder engagement and support for the company’s strategic decisions.
The most recent analyst rating on (HK:1513) stock is a Sell with a HK$37.23 price target. To see the full list of analyst forecasts on Livzon Pharmaceutical Group stock, see the HK:1513 Stock Forecast page.
Livzon Pharmaceutical Group Inc. has announced the current positions held by its board of directors and the composition of its board committees. This announcement provides insights into the leadership structure of the company, which could impact its strategic direction and governance. The board includes a mix of executive, non-executive, and independent directors, with various members chairing key committees such as the Audit Committee and the Environmental, Social and Governance Committee. This structure reflects the company’s focus on robust governance and strategic oversight, potentially influencing its market positioning and stakeholder confidence.
The most recent analyst rating on (HK:1513) stock is a Sell with a HK$37.23 price target. To see the full list of analyst forecasts on Livzon Pharmaceutical Group stock, see the HK:1513 Stock Forecast page.
Livzon Pharmaceutical Group announced that 194 of its products have been included in the 2025 National Reimbursement Drug List (NRDL) in China, which is expected to enhance market reach and drug accessibility. This inclusion is anticipated to positively impact the company’s future performance, although it will not materially affect current operations.
The most recent analyst rating on (HK:1513) stock is a Sell with a HK$37.23 price target. To see the full list of analyst forecasts on Livzon Pharmaceutical Group stock, see the HK:1513 Stock Forecast page.
Livzon Pharmaceutical Group has entered into the 2025 Utilities Supplemental Agreement and the 2025 Service Supplemental Agreement with Livzon MAB to adjust the annual caps for connected transactions. The agreements aim to meet Livzon MAB’s operational needs by increasing the maximum amounts for utilities and services provided by the Group. These transactions are subject to reporting requirements under Hong Kong Listing Rules but are exempt from independent shareholders’ approval.
The most recent analyst rating on (HK:1513) stock is a Sell with a HK$37.23 price target. To see the full list of analyst forecasts on Livzon Pharmaceutical Group stock, see the HK:1513 Stock Forecast page.
Livzon Pharmaceutical Group has announced the nomination of Ms. Wang Zhiyao as a candidate for the position of independent non-executive director on its board. Ms. Wang has completed the necessary pre-appointment training and obtained the required certification from the Shenzhen Stock Exchange, with her qualifications and independence reviewed and approved without objection. This move is subject to approval at the company’s general meeting, potentially strengthening the board’s expertise and governance.
The most recent analyst rating on (HK:1513) stock is a Sell with a HK$37.23 price target. To see the full list of analyst forecasts on Livzon Pharmaceutical Group stock, see the HK:1513 Stock Forecast page.
Livzon Pharmaceutical Group Inc. has announced its 2025 first extraordinary general meeting scheduled for December 10, 2025. The meeting will address several key resolutions, including the cancellation of the Supervisory Committee, amendments to the Articles of Association, and the appointment of Ms. Wang Zhiyao as an independent non-executive Director. These changes indicate a strategic shift in the company’s governance structure, potentially impacting its operational efficiency and stakeholder engagement.
The most recent analyst rating on (HK:1513) stock is a Sell with a HK$37.23 price target. To see the full list of analyst forecasts on Livzon Pharmaceutical Group stock, see the HK:1513 Stock Forecast page.
Livzon Pharmaceutical Group Inc. has proposed the election of Ms. Wang Zhiyao as an independent non-executive director to replace retiring directors Mr. Tian Qiusheng and Mr. Wong Kam Wa. Ms. Wang’s appointment is pending approval at the 2025 extraordinary general meeting and is expected to bring her extensive experience in the pharmaceutical and biotechnology sectors to the company, potentially enhancing its strategic direction and governance.
The most recent analyst rating on (HK:1513) stock is a Sell with a HK$37.23 price target. To see the full list of analyst forecasts on Livzon Pharmaceutical Group stock, see the HK:1513 Stock Forecast page.